Strand Therapeutics has announced a $153 million Series B funding led by Kinnevik, with new investors including Regeneron Ventures, ICONIQ, and Amgen Ventures.  The funding will advance Strand’s pipeline, led by STX-001, a programmable mRNA therapy that expresses the cytokine interleukin-12 (IL-12) directly from the tumour microenvironment.   The company recently announced promising initial Phase I […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!